Brivaracetam is primarily used in the treatment of epilepsy, specifically for managing partial-onset seizures in adults and adolescents aged 16 years and older. It functions as an antiepileptic drug by binding to synaptic vesicle protein 2A (SV2A) in the brain, which helps stabilize electrical activity and reduce seizure frequency. It is often prescribed when other antiepileptic medications are ineffective or not well-tolerated. Brivaracetam is available in oral forms such as tablets and liquid solutions, as well as an injectable formulation for use in hospital settings. Its rapid onset of action makes it suitable for acute seizure management. Patients are typically started on a low dose, which is gradually increased based on their response and tolerance. Regular monitoring is recommended to assess efficacy and manage potential side effects.